Boulos M
Departamento de Doenças Infecciosas e Parasitárias da Faculdade de Medicina da USP, Brasil.
Rev Inst Med Trop Sao Paulo. 1993 Jan-Feb;35(1):81-7.
Fluconazole therapy was evaluated prospectively in 108 patients with immunosupression and serious fungal infections. Patients were enrolled if they had a life-threatening fungal infection and conventional therapy had failed to eradicate infection, had caused serious toxic reactions, or was contraindicated. Patients were treated with 50 to over 400 mg/day initially. AIDS was underlying risk factor in 66.6% of the patients evaluated in the study and in 92.9% of 57 patients with cryptococcal infection. Satisfactory clinical response was observed in 43 patients with active cryptococcal infection and in 39 patients with active candidiasis, 90.7% and 92.3% respectively. Concerning mycologic response, 63.3% and 80.7% of 30 patients with cryptococcal infection and 26 patients with candidiasis respectively had final negative cultures. Eleven patients (10.2%) had adverse effects possibly due to fluconazole therapy. Fluconazole may be effective in the treatment of cryptococcal infection and candidiasis and can be an alternative to conventional antifungal therapy.
对108例免疫抑制且患有严重真菌感染的患者进行了氟康唑治疗的前瞻性评估。如果患者患有危及生命的真菌感染且传统治疗未能根除感染、引起严重毒性反应或存在禁忌，则将其纳入研究。患者最初接受50至400毫克/天以上的治疗。在该研究评估的患者中，66.6%的患者存在艾滋病这一潜在危险因素，在57例隐球菌感染患者中，这一比例为92.9%。43例活动性隐球菌感染患者和39例活动性念珠菌病患者分别观察到了满意的临床反应，分别为90.7%和92.3%。关于真菌学反应，30例隐球菌感染患者和26例念珠菌病患者中，分别有63.3%和80.7%的患者最终培养结果为阴性。11例患者（10.2%）可能因氟康唑治疗出现了不良反应。氟康唑可能对隐球菌感染和念珠菌病的治疗有效，可作为传统抗真菌治疗的替代药物。
